Zuckerman J N
Academic Unit of Travel Medicine and Vaccines and Clinical Trials Centre, Royal Free Hospital School of Medicine, London, UK.
J Viral Hepat. 1998 Nov;5 Suppl 2:13-5. doi: 10.1046/j.1365-2893.1998.0050s2013.x.
A new triple-S containing recombinant hepatitis B vaccine was evaluated in terms of immunogenicity and reactogenicity in a cohort of healthy healthcare professionals who were persistent non-responders to the currently licensed hepatitis B vaccines. One hundred subjects were allocated randomly to receive two doses of 5, 10, 20 or 40 micrograms of a new hepatitis B vaccine 2 months apart. The overall seroconversion rate was 70% with a single dose of 20 micrograms of the vaccine being as effective as two doses of either 20 micrograms or 40 micrograms of the vaccine formulation in terms of seroconversion, seroprotection and geometric mean titres.
在一组对目前已获许可的乙肝疫苗持续无应答的健康医护人员中，对一种含重组乙肝疫苗的新型三联疫苗（triple-S）的免疫原性和反应原性进行了评估。100名受试者被随机分配，间隔2个月接受两剂5、10、20或40微克的新型乙肝疫苗。总体血清转化率为70%，就血清转化、血清保护和几何平均滴度而言，单剂20微克的疫苗与两剂20微克或40微克的疫苗制剂效果相同。
